Abstract 13P
Background
According to the SEER cancer statistics from 2013 to 2017, 43.4% of all newly breast cancers are diagnosed in women aged 65 years and older. Despite a relatively high prevalence of older adults with newly diagnosed breast cancer, elderly patients are often under-represented in the pivotal neoadjuvant trials. Recommendations for treatment with neoadjuvant chemotherapy (NAC) are based on subgroup analyses and extrapolation of study results from younger patients.
Methods
This retrospective observational study collected data from the Joint Breast Cancer Registry (JBCR) on older adults aged ≥ 65 years treated with NAC for breast cancer at the National Cancer Centre Singapore from October 2014 to October 2019. Patients in the JBCR had detailed clinical and pathological information including hormone receptor (HR), HER2 status, type of NAC. Outcomes and adverse events were retrieved from electronic medical records. Pathological complete response(pCR) was defined by the absence of residual disease in the breast and lymph nodes following NAC.
Results
Of 353 patients who underwent NAC, 66(18%) patients were older adults aged ≥ 65 years. Patients characteristics are decribed in the table. The median age was 69 (65-83) years. 31(46%) patients had HER2+ disease. 13(19%) were triple negative breast cancer (TNBC). 18(27%) patients were unable to complete NAC, of which 10(15%) were due to side effects while 5 (7.5%) had progressive disease during treatment and the remainder 3(5%) refused the planned treatment. Half of the cohort with HER2+ disease had anthracycline/taxane based chemotherapy along with HER2 directed therapy of either trastuzumab or the combination trastuzumab and pertuzumab. 13 (19%) patients had pCR, 11 were HER2+ while 1 was HR+/HER 2- and the other was TNBC. Table: 13P
Patient characteristics
No. (%) | |
Breast cancer diagnosis that are 65 years and above | 66 (18) |
median age (Range) | 69 (65-83) |
median ECOG(range) | 0 (0-2) |
Clinical T Staging | |
2 | 14 (21) |
3 to 4 | 52 (79) |
Clinical N Staging | |
0 | 14 (20) |
1 to 3 | 51 (79) |
nX | 1 |
HR status | |
Negative | 25(37) |
Positive | 41(63) |
Human epidermal growth factor receptor 2 (HER2) | |
Negative | 35 (54) |
Positive | 31 (46) |
Histology | |
HR+ /HER2- | 22 (33) |
HR +/ HER2+ | 19 (28) |
HR - / HER2+ | 12 (18) |
Triple negativeTNBC (HR- /& HER2-) | 13 (18) |
NACcompleted/ NAC not completed | 48(72) / 18 (27) |
IncompletionReason | |
PD | 5(27) |
Side effects | 10(55) |
Refused treatment | 3 (16) |
Pathological Complete Response | |
Overall | 13(18) |
TNBC | 1 |
Her2+ | 11(17) |
ER +/ HER2- | 1 |
Conclusions
We report a cohort of older adults who had undergone NAC at our centre. Consistent with existing studies, 72 % of the patients completed NAC. In keeping with data on younger patients, older adults with HER2+ breast cancer had higher pCR. However, unlike younger women with TNBC, older adults in this study had lower rates of pCR which was also noted in a recent pooled analysis. This could reflect a heterogeneity of TNBC in older women which warrants further investigations in the future
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
CIRB Singhealth 2019/093/A.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
298P - Abandonment of treatment in teenagers and young adults with cancer: A multi institutional survey
Presenter: B S Ankit
Session: e-Poster Display Session
304P - Identification of nine lncRNAs signature for predicting survival benefit of melanoma patients treated with immune checkpoint inhibitors
Presenter: Jian-Guo Zhou
Session: e-Poster Display Session
305P - Novel co-occurring genomic alterations associated with prediction and prognosis in lung adenocarcinoma
Presenter: Xin Zhao
Session: e-Poster Display Session
306P - Detection of anaplastic lymphoma kinase (ALK) mutations using circulating tumour DNA (ctDNA) in advanced non-squamous non-small cell lung cancer (non-Sq-NSCLC) in Asia
Presenter: Kirsty Lee
Session: e-Poster Display Session
307P - Development of circulating free DNA methylation markers for thyroid nodule diagnostics
Presenter: Shuibing Hong
Session: e-Poster Display Session
308P - The genomic landscape of non-small cell lung cancer (NSCLC) in East Asia using circulating tumour DNA (ctDNA) in clinical practice
Presenter: Byoung Cho
Session: e-Poster Display Session
309P - Improved diagnostic accuracy in MRI breast lesions using a classification system and multilayer perceptron neural network
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
310P - Genomic biomarker detection in East Asian clinical practice using circulating tumour DNA (ctDNA) from patients with gastrointestinal (GI) tract cancers
Presenter: Sadakatsu Ikeda
Session: e-Poster Display Session
311P - Effect of chemotherapy on fatty liver occurrence in breast and gastrointestinal cancer patients
Presenter: Seyed Alireza Javadinia
Session: e-Poster Display Session
312P - Identification of neoantigen-specific T cell response and anti-tumour immunity in pancreatic cancer
Presenter: Xiaoxiao Du
Session: e-Poster Display Session